Robert W. Baird Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target decreased by equities research analysts at Robert W. Baird from $360.00 to $248.00 in a report released on Thursday,MarketScreener reports. Robert W. Baird’s price target would indicate a potential upside of 60.87% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Evercore cut their target price on Insulet from $340.00 to $240.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Sanford C. Bernstein dropped their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday. Royal Bank Of Canada restated an “outperform” rating and issued a $325.00 target price on shares of Insulet in a report on Tuesday, April 14th. The Goldman Sachs Group dropped their price target on shares of Insulet from $326.00 to $277.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday. Eighteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $257.09.

Insulet Price Performance

Shares of NASDAQ PODD opened at $154.16 on Thursday. Insulet has a 1 year low of $148.30 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 2.15. The company’s 50-day moving average is $211.22 and its 200 day moving average is $263.85. The stock has a market capitalization of $10.68 billion, a P/E ratio of 35.85, a P/E/G ratio of 0.92 and a beta of 1.20.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the company earned $1.02 earnings per share. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts expect that Insulet will post 6.46 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Insulet by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares during the last quarter. State Street Corp grew its holdings in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Invesco Ltd. grew its holdings in Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after purchasing an additional 141,167 shares during the last quarter. Finally, Norges Bank bought a new position in Insulet during the 4th quarter valued at about $300,794,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.